Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Hu14.18K322A |
Trade Name | |
Synonyms | |
Drug Descriptions |
Hu14.18K322A is a monoclonal antibody that binds GD2 and activates immune response to tumor cells expressing GD2, potentially resulting in increased tumor cell death (PMID: 32169872, PMID: 31601569). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C80042 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Busulfan + Hu14.18K322A | Busulfan Hu14.18K322A | 0 | 1 |
Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Hu14.18K322A + Vincristine Sulfate | Cisplatin Cyclophosphamide Doxorubicin Etoposide Hu14.18K322A Vincristine Sulfate | 0 | 0 |
Cyclophosphamide + Hu14.18K322A + Topotecan | Cyclophosphamide Hu14.18K322A Topotecan | 0 | 0 |
Hu14.18K322A | Hu14.18K322A | 0 | 1 |